Abstract:Background: Camptothecin (CPT), a pentacyclic alkaloid with antitumor properties, is derived from the Camptotheca acuminata. Topotecan and irinotecan (CPT derivatives) were first approved by the Food and Drug Administration for cancer treatment over 25 years ago and remain key anticancer drugs today. However, their use is often limited by clinical toxicity. Despite extensive development efforts, many of these derivatives have not succeeded clinically, particularly in their effectiveness against pancreatic cancer which remains modest. Aim of the study: This study aimed to evaluate the therapeutic activity of FLQY2, a CPT derivative synthesized in our laboratory, against pancreatic cancer, comparing its efficacy and mechanism of action with those of established clinical drugs. Methods: The cytotoxic effects of FLQY2 on cancer cells were assessed using an MTT assay. Patient-derived organoid (PDO) models were employed to compare the sensitivity of FLQY2 to existing clinical drugs across various cancers. The impact of FLQY2 on apoptosis and cell cycle arrest in Mia Paca-2 pancreatic cancer cells was examined through flow cytometry. Transcriptomic and proteomic analyses were conducted to explore the underlying mechanisms of FLQY2's antitumor activity. Western blotting was used to determine the levels of proteins regulated by FLQY2. Additionally, the antitumor efficacy of FLQY2 in vivo was evaluated in a pancreatic cancer xenograft model. Results: FLQY2 demonstrated (1) potent cytotoxicity; (2) superior tumor-suppressive activity in PDO models compared to current clinical drugs such as gemcitabine, 5-fluorouracil, cisplatin, paclitaxel, ivosidenib, infinitinib, and lenvatinib; (3) significantly greater tumor inhibition than paclitaxel liposomes in a pancreatic cancer xenograft model; (4) robust antitumor effects, closely associated with the inhibition of the TOP I and PDK1/AKT/mTOR signaling pathways. In vitro studies revealed that FLQY2 inhibited cell proliferation, colony formation, induced apoptosis, and caused cell cycle arrest at nanomolar concentrations. Furthermore, the combination of FLQY2 and gemcitabine exhibited significant inhibitory and synergistic effects. Conclusion: The study confirmed the involvement of topoisomerase I and the PDK1/AKT/mTOR pathways in mediating the antitumor activity of FLQY2 in treating Mia Paca-2 pancreatic cancer. Therefore, FLQY2 has potential as a novel therapeutic option for patients with pancreatic cancer.

Improved Anti-Tumor Activity of Fluorinated Camptothecin Derivatives 9-Fluorocamptothecin and 7-Ethyl-9-fluorocamptothecin on Hepatocellular Carcinoma by Targeting Topoisomerase I.

Design, Semisynthesis and Potent Cytotoxic Activity of Novel 10-Fluorocamptothecin Derivatives

Design and synthesis of novel 7-ethyl-10-fluoro-20-O-(cinnamic acid ester)-camptothecin derivatives as potential high selectivity and low toxicity topoisomerase I inhibitors for hepatocellular carcinoma

Two Novel Camptothecin Derivatives Inhibit Colorectal Cancer Proliferation Via Induction of Cell Cycle Arrest and Apoptosis in Vitro and in Vivo

Anti-tumor Effects and Mechanism of a Novel Camptothecin Derivative YCJ100.

Design, Synthesis and Antineoplastic Activity of Novel 20(S)-Acylthiourea Derivatives of Camptothecin.

Progress on the Functional Modification of the Anticancer Drug:Camptothecin

Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Design and synthesis of novel 20(S)-α-aminophosphonate derivatives of camptothecin as potent antitumor agents

Biological impact and therapeutic potential of a novel camptothecin derivative (FLQY2) in pancreatic cancer through inactivation of the PDK1/AKT/mTOR pathway

Design and Synthesis of Novel 7-[(N-substituted-thioureidopiperazinyl)-methyl]-camptothecin Derivatives As Potential Cytotoxic Agents.

Design, Synthesis, Mechanisms of Action, and Toxicity of Novel 20(S)-Sulfonylamidine Derivatives of Camptothecin As Potent Antitumor Agents

Design, Synthesis, and In Vitro/In Vivo Anti-Cancer Activities of Novel (20S)-10,11-Methylenedioxy-Camptothecin Heterocyclic Derivatives

The current status of camptothecin analogues as antitumor agents.

Design, Synthesis, and Cytotoxic Activity of Novel 7-Substituted Camptothecin Derivatives Incorporating Piperazinyl-Sulfonylamidine Moieties.

Trifluoromethyl-promoted homocamptothecins: synthesis and biological activity

Antitumor activity and pharmacokinetics following oral administration of natural product DNA topoisomerase I inhibitors 10-hydroxycamptothecin and camptothecin in SCID mice bearing human breast cancer xenografts.

Topoisomerase I-mediated antiproliferative activity of 10-substituted and 12-substituted homocamptothecins

Low toxic and high soluble camptothecin derivative 2-47 effectively induces apoptosis of tumor cells in vitro

Design and Synthesis of Novel PEG-conjugated 20(S)-Camptothecin Sulfonylamidine Derivatives with Potent in Vitro Antitumor Activity Via Cu-catalyzed Three-Component Reaction

Identification of 7-Aminourea or Aminothiourea Derivatives of Camptothecin As Selective Topoisomerase I Inihibitors with Anti-Colorectal Cancer Activities